Home Featured Page 18

Featured

Latest

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores...

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research...

Psychedelic Insights Playground

Q3’25 Survey: What are Psychedelics Investors Excited About?

The Psychedelic News Feed: October 13 – 19, 2025

September 2025 Psychedelic Patent Update

Psychedelic Funding Update: Q3 2025

EDITOR PICKS

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores...

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research...

Psychedelic Insights Playground

Brad Adams PhD – LAMPS

Q3’25 Survey: What are Psychedelics Investors Excited About?

The Psychedelic News Feed: October 13 – 19, 2025

September 2025 Psychedelic Patent Update

Dreamshadow – Life and Breath

Psychedelic Funding Update: Q3 2025

EDITOR PICKS

The Psychedelic Practitioner Issue 5: Groups in Practice

Psychedelic Policy Briefing: Week of June 16, 2026

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY